A review from China.

ATH has been quite active in this area, but none of its possible results with ATH434 have been published. Professor Finkelstein has published 9 eye-related papers with Dr. Nguyen. Eye diseases are mentioned in the annual report: " and we believe that the platform technology may also be applicable for certain cancers, age-related macular degeneration, diabetes mellitus, cardiovascular disease and other neurodegenerative diseases"..

As most of Finkelstein & Nguyen's papers are related to PD, I would expect that the ape study already completed will once again give us some results on how 434 will act on the retinas of these animals. Finkelstein was one of the authors of these posters about the ape study.

Review

Front Pharmacol

. 2024 Oct 30:15:1489877.

doi: 10.3389/fphar.2024.1489877. eCollection 2024.

Targeting ferroptosis: a novel therapeutic strategy for the treatment of retinal diseases

Xiao-Dan Hao ^{1 2}, Wen-Hua Xu ³, Xiaoping Zhang ⁴, Junqiang Xue ¹

Affiliations Expand

• PMID: 39539617

PMCID: PMC11557320 DOI: 10.3389/fphar.2024.1489877

Abstract

Ferroptosis plays a vital role in the progression of various retinal diseases. The analysis of the mechanism of retinal cell ferroptosis has brought new targeted strategies for treating retinal vascular diseases, retinal degeneration and retinal nerve diseases, and is also a major scientific issue in the field of ferroptosis. In this review, we summarized results from currently available in vivo and in vitro studies of multiple eye disease models, clarified the pathological role and molecular mechanism of ferroptosis in retinal diseases, summed up the existing pharmacological agents targeting ferroptosis in retinal diseases as well as highlighting where future research efforts should be directed for the application of ferroptosis targeting agents. This review indicates that ferroptosis of retinal cells is involved in the progression of age-related/inherited macular degeneration, blue light-induced retinal degeneration, glaucoma, diabetic retinopathy, and retinal damage caused by retinal ischemia-reperfusion via multiple molecular mechanisms. Nearly 20 agents or extracts, including iron chelators and transporters, antioxidants, pharmacodynamic elements from traditional Chinese medicine, ferroptosis-related protein inhibitors, and neuroprotective agents, have a remissioning effect on retinal disease in animal models via ferroptosis inhibition. However, just a limited number of agents have received approval or are undergoing clinical trials for conditions such as iron overload-related diseases. The application of most ferroptosis-targeting agents in retinal diseases is still in the preclinical stage, and there are no clinical trials yet. Future research should focus on the development of more potent ferroptosis inhibitors, improved drug properties, and ideally clinical testing related to retinal diseases.